^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

ATM underexpression

i
Other names: ATM, ATA, ATC, ATD, ATDC, TEL1, TELO1, ATM serine/threonine kinase
Entrez ID:
Related biomarkers:
2ms
STAT3 and PD-L1 are negatively correlated with ATM and have impact on the prognosis of triple-negative breast cancer patients with low ATM expression. (PubMed, Breast Cancer Res Treat)
Locally advanced TNBC with low ATM expression may be more likely to benefit from anti-PD-L1 inhibitors. The feasibility of ATM functional inhibitor combined with immune checkpoint blockade therapies in the treatment of TNBC is also worthy of further exploration. Our study suggests that STAT3 has different impacts on tumor progression in different tumors.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • STAT3 (Signal Transducer And Activator Of Transcription 3) • STAT1 (Signal Transducer And Activator Of Transcription 1)
|
PD-L1 expression • PD-L1 underexpression • PD-L1 negative • ATM underexpression • STAT3 expression • ATM expression
2ms
Interaction between HER2 and ATM predicts poor survival in bladder cancer patients. (PubMed, J Cell Mol Med)
Altogether, our data pinpoint an important biological role of the interconnection between HER2 and ATM. The latter appear to be an independent prognostic biomarker and may serve as targets to develop novel combination therapies to improve the outcome of patients with bladder cancer.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 overexpression • HER-2 mutation • ATM underexpression • ATM expression • HER-2-H
over1year
Downregulation of ATM and BRCA1 Predicts Poor Outcome in Head and Neck Cancer: Implications for ATM-Targeted Therapy. (PubMed, J Pers Med)
The results showed that the expression of ATM and BRCA1 was downregulated in BQ-associated HNC, as the BQ ingredient arecoline could suppress the expression of both genes. Transcriptomic analysis showed that inhibition of ATM kinase by KU55933 induced apoptosis signaling and potentiated cisplatin-induced cytotoxicity. These data unveil poor prognosis in the HNC patient subgroup with low expression of ATM and BRCA1 and support the notion of ATM-targeted therapy.
Journal • BRCA Biomarker
|
BRCA1 (Breast cancer 1, early onset) • HRD (Homologous Recombination Deficiency)
|
ATM underexpression • BRCA1 expression • ATM expression
|
cisplatin • KU-55933 • arecoline
over1year
The Role and Mechanism of ATM-Mediated Autophagy in the Transition From Hyper-Radiosensitivity to Induced Radioresistance in Lung Cancer Under Low-Dose Radiation. (PubMed, Front Cell Dev Biol)
ATM may influence autophagy through p-JNK and AMBRA1 to participate in the regulation of the HRS/IRR phenomenon. Autophagy interacts with the cellular carbon metabolite DL-Norvaline to participate in regulating the low-dose radiosensitivity of cells.
Journal
|
BECN1 (Beclin 1) • MAPK8 (Mitogen-activated protein kinase 8)
|
ATM underexpression • ATM expression • ATM positive
over2years
Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models. (PubMed, Br J Cancer)
ATM loss augments replication catastrophe-mediated cell death induced by ATRi/gem and may predict clinical responsiveness to this combination. ATM status should be carefully assessed in tumours from patients with PDAC, since distinction between ATM-low and ATM-null could be critical in maximising the success of clinical trials using ATM expression as a predictive biomarker.
Preclinical • Journal
|
CHEK2 (Checkpoint kinase 2) • ATR (Ataxia telangiectasia and Rad3-related protein)
|
ATM underexpression • ATM expression
|
gemcitabine • ceralasertib (AZD6738)
over2years
[VIRTUAL] Identification of novel CDK12 inhibitors that synergize with PARP inhibition through induction of ‘BRCAness’ phenotype (AACR-II 2020)
In combination with Olaparib, a clinically approved PARP inhibitor, we observed a synergistic effect on cell viability in the OV-90 ovarian cancer cell line...Overall the compounds demonstrate a phenotype consistent with selective CDK12 inhibition and cellular potency that compares favorably with other published compounds. The compounds have a high potential for being developed as once-daily oral compounds for use in combination with PARP inhibition, immunomodulators and as single agent therapy.
BRCA Biomarker • PARP Biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • CDK12 (Cyclin dependent kinase 12) • RAD51 (RAD51 Homolog A) • ATR (Ataxia telangiectasia and Rad3-related protein) • BRCA (Breast cancer early onset) • CDK1 (Cyclin-dependent kinase 1)
|
ATM underexpression • ATM expression
|
Lynparza (olaparib)